OppenheimerFunds’s Acorda Therapeutics ACOR Stock Holding History

OppenheimerFunds’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$247K	Buy	155 +3	+2%	+$5.41K	﹤0.01%	1633
2018 Q4	$285K	Sell	152 -36	-19%	-$78.3K	﹤0.01%	1593
2018 Q3	$444K	Buy	188 +90	+92%	+$279K	﹤0.01%	1503
2018 Q2	$336K	Sell	98 -22	-18%	-$67.4K	﹤0.01%	1573
2018 Q1	$340K	Sell	120 -29	-19%	-$86.8K	﹤0.01%	1548
2017 Q4	$383K	Buy	149 +10	+7%	+$28.4K	﹤0.01%	1602
2017 Q3	$394K	Sell	139 -56	-29%	-$148K	﹤0.01%	1618
2017 Q2	$462K	Buy	195 +77	+65%	+$153K	﹤0.01%	1539
2017 Q1	$298K	Sell	118 -10	-8%	-$28.8K	﹤0.01%	1716
2016 Q4	$288K	Buy	+128	New	+$304K	﹤0.01%	1618
2016 Q3	–	Sell	-74	Closed	-$226K	–	1763
2016 Q2	$226K	Buy	+74	New	+$241K	﹤0.01%	1573
2016 Q1	–	Sell	-52	Closed	-$267K	–	1746
2015 Q4	$267K	Buy	+52	New	+$227K	﹤0.01%	1566

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

OppenheimerFunds's ACOR Position: Q1 2019 in Review

OppenheimerFunds increased its Acorda Therapeutics (ACOR) stake by 2% in Q1 2019, buying an estimated $5.41K and bringing the position to 155 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #1633.

OppenheimerFunds first reported a position in ACOR in Q4 2015 and has held it in 12 quarters since. The position peaked at $462K in Q2 2017. 184 funds tracked by Wall St. Rank hold ACOR as of Q1 2019.

OppenheimerFunds held 155 shares of Acorda Therapeutics worth $247K as of Q1 2019.
OppenheimerFunds bought 3 Acorda Therapeutics shares in Q1 2019, an estimated $5.41K.
Acorda Therapeutics made up ﹤0.01% of OppenheimerFunds's portfolio in Q1 2019, its #1633 holding.
OppenheimerFunds first reported a position in Acorda Therapeutics in Q4 2015 and has held it in 12 quarters since.
OppenheimerFunds's Acorda Therapeutics position peaked at $462K in Q2 2017.
184 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.